This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Solar's Short Squeeze Days Are Numbered

Revenue in 2013 increased as a result of moving part of the large Desert Sunlight project from 2014 to 2013. Wall Street is a big fan of getting paid today instead of tomorrow.

For tomorrow, actually 2015, investors clearly keyed in on the potential earnings of up to $6 a share. The guidance given is $4-$6 a share, but who is going to remember in 2015, right? You can drive a steamship full of Chinese subsidized solar panels through that figure.

In 2013, analysts have an earnings estimate of $3.46 a share on $3.15 billion in sales. This is where we find the market moving difference. First Solar is reporting guidance of $2.5-$4 earnings a share on $3.5-$4 billion in sales.

After reading the increase in guidance and profit for 2013, you may be tempted to buy into the long thesis and say "this time is different and the price spike is real." But remember, "what the large print gives, the small print takes away".

The difference in 2013 guidance is more a result of moving revenue and profits from 2014 to 2013 than an increase in overall revenue and income. The Street will quickly figure this out, and the time to own First Solar is after, not before.

There is an old saying on Wall Street, "buy when there is blood in the streets." This is equally true for short selling, and we all know the blood is flowing after today.

Disclosure: The author doesn't hold a position in any stock mentioned.

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
FSLR $49.71 0.00%
AAPL $130.28 0.00%
FB $79.19 0.00%
GOOG $532.11 0.00%
TSLA $250.80 0.00%

Markets

DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs